NSE: MANKIND | BSE: 543904

Expensive Performer

Download real time

2261.80 -47.30 (-2.05%)

High volume today

NSE 07 Nov, 2025 3:31 PM (IST)

93,357.7

Market Cap

High in industry

0.6

Beta 1Year

Very Low volatility

Margin Decline

Mankind Pharma's Q2FY26 net profit declines 21.7% YoY, EBITDA margin contracts 280 bps YoY to 25% See details

Mankind Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for MANKIND, BSE:543904 Mankind Pharma Ltd.

Search Inside the pdf :

Mankind Pharma Ltd.

01 Aug 2025

2261.80

-2.05%

Cost headwinds lead to earnings miss

Buy: Mankind Pharma Ltd.

Target

Motilal Oswal

Mankind Pharma (Mankind) reported in-line revenue in 1QFY26. However, EBITDA/PAT came in 5%/7% below our estimates.

Mankind Pharma Ltd. has an average target of 2840.50 from 2 brokers.

Mankind Pharma Ltd.

22 May 2025

2261.80

-2.05%

Higher marketing/promotional costs drive a miss

Buy: Mankind Pharma Ltd.

Target

Motilal Oswal

Mankind Pharma (Mankind) delivered in-line revenue in 4QFY25; however, EBITDA/PAT came in 14%/12% below our estimates. Higher-than-expected spending on marketing and promotional activities affected the company’s 4Q performance.

Mankind Pharma Ltd. is trading at high day volume of 870.3K.

Mankind Pharma Ltd.

26 Mar 2025

2261.80

-2.05%

MANKIND PHARMA LIMITED

Accumulate: Mankind Pharma Ltd.

Geojit BNP Paribas

Mankind Pharma Ltd. has an average target of 2840.50 from 2 brokers.

Mankind Pharma Ltd.

25 Jan 2025

2261.80

-2.05%

Laurus Lab (LAURUS) significantly beat our earnings estimates in 3QFY25, led by a scale-up in the CDMO segment. Commercial supplies (including launch quantities) led to strong 89% YoY growth in CDMO sales for the quarter.

Buy: Mankind Pharma Ltd.

Target

Motilal Oswal

Mankind Pharma (Mankind) delivered in-line operational performance for 3QFY25. The earnings were below estimates due to higher interest outgo on debt raised to fund the BSV acquisition.

Number of FII/FPI investors decreased from 648 to 627 in Sep 2025 qtr

Mankind Pharma Ltd.

05 Nov 2024

2261.80

-2.05%

Superior execution in consumer wellness/exports drives beat on 2Q estimates

Buy: Mankind Pharma Ltd.

Target

Motilal Oswal

Mankind Pharma (MANKIND) delivered better-than-expected 2QFY25 performance, fueled by a strong revival in growth of the consumer business and continued growth momentum in the exports business.

Mankind Pharma Ltd. is trading at high day volume of 870.3K.

Mankind Pharma Ltd.

23 Aug 2024

2261.80

-2.05%

FundsIndia

Mankind Pharma Ltd. is trading at high day volume of 870.3K.

Mankind Pharma Ltd.

23 Aug 2024

2261.80

-2.05%

Improvising the base; adding new avenues for growth

Buy: Mankind Pharma Ltd.

Target

Motilal Oswal

MANKIND has a strategic roadmap for growth through expansion in high entry barrier innovative product launches in the chronic/consumer segment and other adjacencies, transitioning from sexual wellness to consumer wellness in the over-the counter (OTC) space.

Number of FII/FPI investors decreased from 648 to 627 in Sep 2025 qtr

Mankind Pharma Ltd.

26 Jul 2024

2261.80

-2.05%

Unlocking new vertical through BSV acquisition

Buy: Mankind Pharma Ltd.

Motilal Oswal

Mankind Pharma has agreed to acquire Bharat Serum Vaccines (BSV) for EV of INR136b, implying EV/EBITDA of 28x/22-23x on FY24/FY25 basis.

Mankind Pharma Ltd. is trading below all available SMAs

Mankind Pharma Ltd.

13 Jun 2024

2261.80

-2.05%

Disruptor with a dose of care

Buy: Mankind Pharma Ltd.

Motilal Oswal

In a span of 30 years, Mankind Pharma (MANKIND) has built a robust domestic
formulation (DF) franchise and become the fourth largest player by market share.

Mankind Pharma Ltd. has an average target of 2840.50 from 2 brokers.

Mankind Pharma Ltd.

26 Apr 2023

2261.80

-2.05%

IPO DETAILS

IPO Subscribe: Mankind Pharma Ltd.

Marwadi Financial Services

Considering the TTM (Dec-22) /FY23 Annualized EPS of Rs 29.61/33.16 on a post-issue basis, the company is going to list at a P/E of 36.47/32.57x with a market cap of Rs. 4,32,636 mn. whereas its peers namely Sun Pharmaceuticals, Cipla, Alkem Lab and Torrent Pharmaceutical are trading at a P/E of 29.43x, 27.45x, 39.24x, 43.65x.